NEW YORK (GenomeWeb News) - Qiagen has agreed to a new marketing partnership with Pathway Diagnostics and has entered into a research agreement with Sequenom, the company said today.
Under the agreement with Malibu, Calif.-based Pathway, Qiagen said the companies will offer customers a bundled solution of Qiagen's assays and Pathway's clinical development and testing services, Qiagen said. Qiagen said it will use its sales force to "develop project opportunities" for the companies to address jointly.
The company added that it hopes the partnership will enhance the "clinical utility of new biomarkers through comprehensive assay development, sample-to-result qualification and clinical validation of genetic, pharmacogenomic, metabolomic and toxicogenomic biomarkers."
Separately, Qiagen said that it has agree to work with Sequenom to develop a preanalytical solution to enrich nucleic acids for prenatal diagnostics, Qiagen said.
Sequenom will retain commercial rights to any tests the companies develop under the partnership.
Qiagen said the goal for the Sequenom partnership is to develop reliable reagents for the enrichment of small nucleic acid fragments, such as those found in maternal plasma, for analysis of cancer and other disorders.
Financial terms of the agreements were not released.